Analysts at Jefferies downgraded AcelRx Pharmaceuticals, Inc. ACRX from Buy to Hold.
The price target for AcelRx Pharmaceuticals has been lowered from $12.00 to $6.00.
AcelRx Pharmaceuticals shares have dropped 53.70% over the past 52 weeks, while the S&P 500 index has surged 11.34% in the same period.
AcelRx Pharmaceuticals' shares fell 0.91% to $5.46 in after-hours trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in